Wharton’s Jelly – how does it work?
THURSDAY, 16 SEPTEMBER 2021 / PUBLISHED IN BLOG
What is Wharton’s Jelly?
Wharton’s Jelly is the substance that helps lubricate and support the umbilical cord. What makes Wharton’s Jelly so special is it contains high levels of mesenchymal stem cells. These special stem cells adapt to fit the cells needed to help regenerate damaged tissue and relieve pain naturally.
The Potency of Mesenchymal Stem Cells in Wharton’s Jelly
The mesenchymal stem cells that come from Wharton’s Jelly are among the most potent stem cells, rich in regenerative properties. Wharton’s Jelly also contains a good amount of collagen, hyaluronic acid, and anti-inflammatory properties, making them quintessential in regenerative medicine.
The Role of Regenerative Medicine
Regenerative medicine refers to treatments and medicine that are naturally occurring, including stem cell therapies. Mesenchymal stem cells are harvested from the Wharton Jelly found in the umbilical cord, donated by a healthy mother of a full-term baby. These stem cells contain all the regenerative properties needed to help the body heal and relieve pain naturally.
How Does Wharton’s Jelly Treatment Work?
Mesenchymal stem cells are injected into the body and have the ability to transmute into cells needed to repair damaged tissue and relieve inflammation. These cells harness potent regenerative properties that help rebuild the injured part of the body and provide long-lasting natural pain relief. Unlike pain medicines, which provide temporary relief that masks the symptoms and can be harmful if taken long-term, the stem cells found in Wharton’s Jelly are naturally occurring and natural to the body.
Best Uses for Wharton’s Jelly
Wharton’s Jelly is best used in patients with degenerative diseases and musculoskeletal injuries. The anti-inflammatory and regenerative properties work to repair damaged tissues, leading to lasting pain relief and restored function.
What to Expect from Wharton’s Jelly Treatment
Once a patient and doctor have decided on this type of stem cell treatment, patients can expect a relatively painless process. Stem cells are injected into the site and immediately go to work. Injections are virtually painless, and there are no known negative side effects. Patients can generally get right back to the activities they love. Doctors will discuss treatment plans based on individual needs, and in some cases, resting an injured area for a specific period may be needed.
The Effectiveness of Wharton’s Jelly Therapy
The mesenchymal stem cells found in Wharton’s Jelly have proven to be a very successful therapeutic method to treat several degenerative issues and injuries. This therapy is relatively painless, with no known negative side effects, making it an excellent choice in treatment. Instead of masking the pain with dangerous medicine, stem cell therapy offers a naturally occurring solution that aims to repair the damaged tissue and resolve the problem.
Learn More About Wharton’s Jelly Treatment
If you want to learn more about Wharton’s Jelly Treatment and how you can help your patients, you can check our next training course here: Wharton’s Jelly Training Course.
- Published in Blog
Global Stem Cells Group Announces Partnership with Bioscience Cell Factory
Just earlier this week, Global Stem Cells Group has signed a historic agreement with a company known as Bioscience Cell Factory– this Dubai-based healthcare company will allow GSCG to act as their representatives operating in both the Middle East and Latin America. Through the acquisition of proprietary branding rights Global Stem Cells Groups will become committed to promote the widespread use of cellular therapy treatments that utilize Mesenchymal Stem Cells (MSCs).
This partnership is groundbreaking in nature, and promises to lead to a wide proliferation of cellular therapies in both the Middle East and Latin America, two regions that are rapidly developing, with a constantly-advancing standard of medical care. Global Stem Cells Group will be clinically equipped with the highest standards and quality procedures as set forth by the Bioscience Cell Factory, resulting in nothing but the best treatment methods available for patients around the world.
“I’m extremely excited about this partnership,” Said Benito Novas, CEO of the Global Stem Cells Group, “Bioscience Cell Factory is one of the most professional and scientifically-focused teams that I’ve ever had the pleasure of working with– I am looking forward to the start of what will be an extremely beneficial professional relationship that will provide our global reach with the quality of Bioscience’s laboratory,”
Indeed, the two firms are also announcing plans to do research together into the nature of adult Mesenchymal Stem Cells, and the benefits that they hold for the medical field. Through the training of physicians and the handling of cell samples in their laboratory, there are high hopes for the advancement of the field of regenerative medicine research. As one of the representatives of the Bioscience Cell Factory abroad, Global Stem Cells Group will further its goal of being a global leader in the regenerative medicine field.
About Bioscience Cell Factory
Bioscience Clinic is a global healthcare company that is based in Dubai, committed to the running of a laboratory for the banking and use of all sorts of allogeneic and autologous cellular products. Through the proliferation of cellular therapies throughout the world, Bioscience Clinic hopes to advance treatment options for some debilitating diseases that current medical science has been largely unable to target the root causes of.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
- Published in News
Global Stem Cells Group Announces Training in Cochabamba, Bolivia at the End of November
The Global Stem Cells Group, a multi-disciplinary community of scientists and physicians that are collaborating to treat diseases and lessen human suffering through the advancement of the field of regenerative medicine has announced that the construction of their Stem Cell Center in Cochabamba, Bolivia, has concluded. What’s more, the organization has announced that, in celebration of the facility’s completion, the Center’s inaugural training course will take place at the end of November.
The new facility located in Bolivia is the 35th Stem Cell Center in the world, strengthening the Global Stem Cells Group’s presence worldwide as they seek to expand research for and the
practice of regenerative medicine across the globe. Representatives from the Group and local physicians in the area will both see the impact of this new clinic, which will offer a permanent space within the country where experts in the field can train Bolivian physicians in the latest stem cell research.
“I am very excited for the opportunity to train more Bolivian physicians. We’ve been laying the groundwork for this Stem Cell Center for a very long time, and it feels almost like a dream to have to ready to unveil to the world by the end of November,” Said Benito Novas, founder and CEO of the Global Stem Cells Group, “To be able to have a permanent location in Cochabamba, and to have spots quickly filling up for this training– I think it speaks volumes to the future of regenerative medicine being a bright one,”
This inaugural training is intended to not only teach physicians the value of incorporating regenerative medicine into their own clinics, but to ensure that there is a vast store of all the necessary equipment and supplies that are required for the wide array of cellular therapies that are available for patients around the world– including a highly interactive study session that goes over the extraction, isolation, and application of PRP, Adipose, ad Bone Marrow Stem Cells.
The Center will also provide access to several texts detailing procedure processes and treatment options that are available for reference after the training is completed.
If you are interested in learning more about the Global Stem Cell Group’s Onsite Regenerative Medicine Training, or to book your seat, you can visit us at our training website
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
- Published in News
ISSCA Announces Speaker’s List for 7th Annual Symposium
The International Society for Stem Cells Applications has officially announced and published its list of speakers for its 7th Annual Regenerative Medicine Symposium. The seventh event of its kind, it is another effort from the iSSCA to bring together a network of regenerative medicine practitioners from all over the world. At previous events, hundreds of physicians came to share in their knowledge regarding cellular therapies and the patients whose lives they can change, and the aim of this year is no different– of course, as a reunion of medical professionals, several steps will be taken to ensure proper social distancing measures, as well as frequent opportunities for sanitation.
As with previous editions of the event, the topics discussed and speakers involved have been updated and edited in an effort to reflect the changing of time and the rapid evolution of the field of regenerative medicine. That is why this symposium will focus on Cellular Therapies During and After the Pandemic. Coronavirus has changed life as we know it, but the scientific and medical communities have not stopped researching. In fact, cellular therapies have been an invaluable asset in managing the largest pandemic in modern history, due to their implications in treating respiratory failure and managing some of the complications induced by exposure to COVID-19. This has resulted in accelerated pathways for regulatory approval and increased funding for new regenerative medicine-based clinical trials, which will all be discussed in greater depth at the event.
But the Regenerative Medicine Symposium also provides a valuable networking opportunity for physicians in the Latin American community. “Here, people interested in cellular therapy can find everything they need to get on the right path to helping people with regenerative medicine,” Said Benito Novas, VP of Public Relations, ISSCA, “If you’ve done some research yourself, or really have no idea where to start– this would be the place. We’ve got vendors, instructors, and interview panels with several distinguished researchers,”
About ISSCA
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine.
Their code of ethics emphasizes principles of morals and ethical conducts.
At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.
For more information, please visit us at www.issca.us or send an email to info@stemcellsgroup.com.
- Published in News
Global Stem Cells Group To Start Training Physicians In Lisbon, Portugal as Early as Sep. 2020
The Global Stem Cells Group has at last finalized discussions to open a The Stem Cell Center Network site in Lisbon, portugal. The Stem Cell Center operates an international network of regenerative medicine practitioners that is dedicated to sharing information with the end goal of bringing cutting-edge regenerative medicine-based treatments to patients suffering from debilitating disease.
The new Portuguese Stem Cell Center will be comprised of a highly-accredited, state of the art clinic/laboratory manned by physicians and scientists with combined decades of experience. It will be another strong foothold in Iberia for the global company, and carries with it full license to use the Group’s proprietary treatment methods and branding designs.
This will be the Global Stem Cell Group’s first permanent location in Portugal, rounding out the company’s presence in Western Europe and the Portuguese-speaking market with the new Lisbon-based partnership. The Stem Cell Center Network continues to roll out new membership opportunities, programs, and events, and our membership has grown steadily year after year– To date, we are present in twenty five countries and five continents.
And to commemorate this partnership the Stem Cell Network has plans to open the clinic in September of 2020, and begin training physicians shortly after. “We’ve wanted to expand into Portugal for a very long time,” Said Benito Novas, Founder and CEO, Global Stem Cells Group, “Now that the world is tentatively opening up, it seemed like a good time to resume teaching physicians– after all, with more people getting sick, it is important for their doctors to have all the tools at their fingertips to help,”
Barring any extenuating circumstances, the Stem Cell Center Network remains scheduled to open in the first week of September, with bookings already being accepted for the Network’s inaugural training at this clinic. With limited availability due to current social distancing efforts, spots are filling up quickly, and prospective applicants are encouraged to sign up soon for the hands-on training course.
To Sign Up Today, Visit us At: www.issca.us
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
- Published in News
Global Stem Cells Group CEO Benito Novas Confirmed Speaker at 1st Ibero-American Fellowship Program in Regenerative and Functional Medicine
The First International Iber-American University Diploma has been announced to focus on laser therapy, hormone therapy, and wellness, and brings with it over a dozen seasoned instructors. The fellowship program, which spans over multiple weeks, covers a variety of topics with the focus of expanding the professional vision of medical professionals, and furthering knowledge of the applications of lasers in gynecology and cosmetic medicine. Additionally, it will update physicians on the newest techniques developed around the world to improve the quality of life of patients. A variety of protocols will be covered, including office, operating room, and hormone-based procedures.
The Fellowship Program has been certified by Atlantic International University, which is a private university based in Honolulu, Hawaii. Those physicians who complete the fellowship will be asked to demonstrate their knowledge through the use of clinical case studies involving real patients. Additionally, AIU offers students the opportunity to supplement this program with resources in various areas of knowledge, at no extra cost.
Benito Novas, CEO of Global Stem Cells Group, had this to say about the conference: “I am extremely proud and excited to be bringing this conference to physicians around the world. The program has been organized and directed by dear friends of mine, who have put in countless hours to ensure over a dozen physicians from a wide variety of specialties– really, nearly every field of medicine will be represented, and the course has been structured to ensure maximum retention for each and every student of ours,”
As a result, Global Stem Cells Group and the International Society for Stem Cells Application have both officially endorsed the course as a way for a physician to increase his knowledge in subjects ranging from cosmetic surgery, to marketing strategies, to hormone therapy, and everything in between. To learn more about the First International Ibero-American University Diploma, you may send an email to aiu-curso@amgerweb.com.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
- Published in News
ISSCA to Launch Regenerative Medicine Studies Program in Collaboration with Medicel Chile
International Society for Stem Cell Application ISSCA to Launch Postgraduate Studies Program in Stem Cell Therapies and Regenerative Medicine in Collaboration with Medicel Chile
ISSCA and Medicel, Inc. have announced plans to launch a post-graduate studies program in stem cell and regenerative medicine, to be conducted in Santiago Chile February 2021.
MIAMI, July 20 , 2020— The international Society for Stem Cell Application ISSCA and Medicel Chile have announced plans to launch a post graduate studies program in stem cell therapies and regenerative medicine in 2020.
The program will include Seven days of intensive, interactive training coursework with classroom instruction and laboratory practice through didactic lectures, hands-on practical experience in laboratory protocols and relevant lessons in regulatory practices. Medicel’s Chief Scientific Officer and Other leading Scientists will teach the coursework and perform laboratory instruction, accompanied by a series of guest lecturers from the Global Stem Cells Group faculty of scientists.
Attendees will receive hands-on training in techniques for a variety of laboratory processes, and gain insight into the inner workings of a cGMP laboratory and registered tissue bank. Regenerative medicine experts with more 15 years of experience in the field will train attendees and provide the necessary tools to implement regulatory and clinical guidelines in a cGMP laboratory setting
The graduate course will be scheduled 3 times during 2020 starting February 23rd
“ Our end goal in Launching this Fellowship program is to help physicians that are looking for really advanced and formal training in Cellular Therapies and Regenerative Medicine — We want to provide them the necessary skills and in depth specialization that is lacking in our smaller point of care programs ,” noted Benito Novas ISSCA Public Relations Director
To learn more about the February 2020 certification event in Santiago, or any of the other upcoming certification courses around the world, visit the ISSCA website.
About the International Society for Stem Cells Applications (ISSCA)
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine.
Incorporated and Trademarked in the United States of America as a non-profit entity, ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine.
Their code of ethics emphasizes principles of morals and ethical conducts. ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.
For more information, please visit the ISSCA’s website or send an email to info@stemcellsgroup.com www.stemcellsgroup.com
About Medicel Chile
Medicel Chile is one of the premiere regenerative medicine treatment centers in the country of Chile, conveniently located in Santiago de Chile, one of the largest metropolitan areas in Latin America. Medicel carries with it a reputation as one of the most scientifically advanced and professional regenerative medicine Laboratories in Chile, and this is in no small part due to its highly-qualified team of scientists and medical professionals and advisers, who research tirelessly to head new breakthroughs in the fields of cellular therapy and cryopreservation, which is the freezing of a stem cell sample to ensure its longevity and freshness, should the patient receiving the service ever wish to use their frozen cells for some future malady.
- Published in News
Global Stem Cells Group has Announced an Agreement with Rokit Healthcare
Global Stem Cells Group announces an agreement with the South Korean biotechnology giant known as Rokit Healthcare to represent the company’s technology in the Latin American market.
The Global Stem Cells Group (GSCG) a world leader in Regenerative Medicine Technologies has signed an agreement with South Korean-based Rokit Healthcare, an esteemed bioprinter manufacturer that is committed to advancing the field of regenerative medicine and bettering the quality of life of people around the world.
The field of bioprinting is an extremely new one, but it shows great promise. Simply, it is the automated, computer aided deposition of bio-materials (which are cells, growth factors, and biocompatible polymers) for the manufacturing of functional human tissues or organs. Growth factors are harvested and used with a proprietary printing technology to create or regenerative damaged or diseased organs. Rokit Healthcare does this primarily through the proliferation of a machine that they dub an ‘organ regenerator’– it looks like a 3D printer, but instead of using plastics to create things, they use cells and materials that will be safe to implant within the human body.
The process of 3D bioprinting human tissues and organs is a revolutionary technology in the field of tissue engineering. One of the major challenges in regenerative medicine research and tissue engineering is mimicking the micro and macro environment of human tissues. In response to this challenge, advances in additive manufacturing have inspired scientists in Korea to develop novel bioprinting technology, for human tissues and organs
With the advancements of 3D printing and regenerative medicine working together, the potential is seemingly limitless for the spreading of bioprinting technology, a process that is known as 4D Printing– and Global Stem Cells Group, in an effort make this revolutionary technology available to patients, has forged an agreement with Rokit Healthcare to promote, and distribute the company’s technology in Latin America-
The Invivo 4D Printer is Rokit Healthcare’s flagship product, and it is one that revolutionizes the application of regenerative medicine and growth factor-based therapies. creating a solution for personalized and improved patient care. By leveraging a combination of 3D and bioprinting technologies, it can better distribute a patient’s autologous tissues and cells, making it an invaluable tool for those that are looking to improve the efficacy of their results, especially for certain dermatological conditions including scarring.
“We’re extremely excited about this new opportunity and look forward to working with Rokit,” Says Benito Novas, CEO of the Global Stem Cells Group, “The Invivo 4D Printer is in a position to turn the practice of regenerative medicine onto its head, and we are planning on creating a training center in Cancun, Mexico exclusively to showcase and instruct other physicians in this cutting-edge technology,”
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for regenerative medicine solutions that adhere to the highest medical standards.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV.
https://finance.yahoo.com/quote/mssv/
About ROKIT :
ROKIT Healthcare is a global healthcare company that is committed to providing an effective and autologous organ regeneration platform. In order to undertake this daunting task, the company uses proprietary biofabrication technologies that show promise in treating several types of diseases in the field of regenerative medicine. Through the proliferation of 4D bioprinting technology, autologous stem cell technologies, ROKIT Healthcare believes that supplying an avenue for organ regeneration will drastically change the way that everyday people trust and manage their own body.
- Published in News
ISSCA Announces New Buenos Aires Symposium
The International Society of Stem Cell Applications (ISSCA) has hereby announced the date of it’s seventh Symposium of Regenerative Medicine. As before, the organization hopes to bring together a network of regenerative medicine practitioners from all over the world to foster a growth of knowledge among them. It will go over a wide range of topics related to regenerative medicine, chiefly among them will be the response of all levels of regenerative medicine research and practice in the COVID-19 pandemic, as well as what the future looks like for the field as a result of it. In addition to this, the symposium will also cover breakthroughs in the field, new treatment options and technological developments that are now available to both doctors and patients.
Cellular Therapies During and After the Pandemic
Cellular therapies have been an invaluable asset in managing the largest pandemic in modern history. This has been evidenced by the use of Mesenchymal cells, along with other growth factors and types of cells, to treat respiratory failure and manage some of the complications induced by exposure to COVID-19. This has resulted in accelerated pathways for regulatory approval and increased funding for new regenerative medicine-based clinical trials.
We are living in a unique time for regenerative medicine, as advancements are being made month after month, year after year at a rapid, exponential rate. Keeping track of the latest advancements in this research and development, and the medical protocols that occur as a result, is critical to safeguarding lives all over the world. Every medical society’s purpose is, primarily, to promote the growth of both their members and the field that they operate in. The International Society for Stem Cell Applications (ISSCA), strives to do just that. In the interest of designing the future of cellular therapies in a post-pandemic world, ISSCA invites pioneers of the field from around the world to form and share in a platform of experiences, knowledge, and progress.
Stem Cells Group to Host Regenerative Medicine Symposium in Buenos Aires, Argentina November 28th
After a period of silence brought about by the global COVID-19 pandemic, the Global Stem Cells Group (GSCG) is prepared to begin bringing medical professionals together by hosting a Regenerative Medicine Symposium in Buenos Aires, Argentina. The Symposium will take place at the Hotel Panamericano, Buenos Aires, on the 28th of November.
The Buenos Aires symposium will feature a wide variety of educational resources, including lectures and demonstrations, as well as product information. All of this is aimed at doctors that are looking to incorporate regenerative medicine into their practices. Industry experts will be on hand to impart the latest information on the newest compounds in the allogeneic stem cell market, including exosomes, amniotic fluid compounds, and umbilical cord blood products. Allogeneic compounds have steadily been increasing in popularity within the field of regenerative medicine, and this is due to their increased safety and treatment efficacy as research has evolved. With this in mind, GSCG representatives will be on hand to give physicians the opportunity to learn more about these popular treatment solutions and how they can be utilized in their own practices.
ISSCA CEO Benito Novas had this to say about the upcoming event: “We’ve barely even scratched the surface of potential for regenerative medicine, which is why it’s so important that we collectively gather and learn about what we’ve done thus far. This is a South
American congress that will witness some of the greatest regenerative doctors of our time
giving once-in-a-lifetime addresses to those in attendance.”
Among these speakers are Drs. Damian Siano, Silvina Pastrana, and Maritza Novas. Dr. Siano will look specifically at sports injuries, and draw on his experience as a sports medicine specialist aiding professional athletes in the world today. Dr. Pastrana, the Medical Director of the Buenos Aires Stem Cells Center, will speak about how stem cells can help to assuage aesthetic conditions. Dr. Novas, an ISSCA Fellow in Cell Therapy and Tissue Engineering, will look at the fundamentals of stem cell biology and their clinical applications. She will cover a broad range of topics concerning MSCs during their transition from bench-side to bedside.
In addition to the wide array of educational sessions offered, the Buenos Aires symposium will also provide a wide array networking and social opportunities for those physicians in attendance. To learn more about ISSCA’s upcoming Buenos Aires Symposium, or to register for the event, visit us at: https://www.issca.us/
About ISSCA
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine.
Their code of ethics emphasizes principles of morals and ethical conducts.
At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.
For more information, please visit https://www.issca.us/ or send an email to info@stemcellsgroup.com
- Published in News
ISSCA Announces its 2020 Schedule of Regenerative Medicine Congresses
The group will host six events across the globe, combining networking and education for practitioners of regenerative medicine
MIAMI LAKES, Florida— The International Society for Stem Cell Application (ISSCA), a worldwide leader in regenerative medicine education, has announced its slate of 2020 medical congresses. The group’s calendar includes dates at six locations across the globe
Through its congresses, the ISSCA seeks to create a platform through which physicians can collaborate, share data, initiate discussions, and exchange information that may be directly translated to therapeutic applications. All doctors who want to share their medical research are welcome to attend, and the ISSCA welcomes abstract submissions and reviews them on a continuing basis.
For the second year straight, the main topic discussed at ISSCA’s congresses will be how cellular products derived from birth tissue (allogeneic compounds) have revolutionized the industry by delivering safer, shorter stem cells procedures for practitioners. During each event, lecturers will respond to concerns attendees have about how regenerative medicine advances will satisfy FDA regulations and how new technologies could continue to help patients under new FDA laws.
This year, the ISSCA welcomes three new cities to its agenda—Salvador de Bahia, Brazil; Punta del Este, Uruguay; and Jakarta, Indonesia. The six congresses are as follows:
- May 2020: Mexico City, Mexico
- June 2020: Caracas, Venezuela
- August 2020: Salvador de Bahia, Brazil
- October 2020: Buenos Aires, Argentina
- November 2020: Jakarta, Indonesia
- December 2020: Punta del Este, Uruguay
“We at the ISSCA are looking forward to this year’s calendar of congresses, which will provide invaluable networking and educational opportunities to physicians looking to expand their knowledge on current innovations and best practices concerning regenerative medicine,” noted Benito Novas, ISSCA VP of Public Relations. “Our global congresses expand on ISSCA’s mission to continue to serve as the premier educational resource for physicians across the globe looking to introduce stem cells treatments into their practices.”
To learn more about the ISSCA or to register for an upcoming congress, visit www.issca.us.
- Published in News
- 1
- 2
